Shivani Srivastava

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

D. Schadendorf, P. Ascierto, E. Lipson, 2022, The New England journal of medicine.

Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma.

L. Hernandez-Aya, J. Collins, B. Nordstrom, 2022, Future oncology.

New insights into development and mortality of COVID‐19‐associated pulmonary aspergillosis in a homogenous cohort of 1161 intensive care patients

R. Dhiman, A. Tiwari, O. Sanjeev, 2022, Mycoses.

Prevalence of sleep apnea and lung function abnormalities in patients with acromegaly

S. Gupta, Ajmal Khan, Z. Neyaz, 2021, Lung India : official organ of Indian Chest Society.

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

D. Schadendorf, P. Ascierto, E. Lipson, 2021 .

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

Biophysical modeling and diffusion kurtosis imaging reveal microstructural alterations in normal-appearing white-matter regions of the brain in obstructive sleep apnea

Z. Neyaz, Shivani Srivastava, Zia Hashim, 2024, Sleep advances : a journal of the Sleep Research Society.